|dc.contributor.author||Januszewski, Andrzej S||-|
|dc.contributor.author||Jenkins, Alicia J||-|
|dc.contributor.author||Sullivan, David R||-|
|dc.contributor.author||Barter, Philip J||-|
|dc.contributor.author||Scott, Russell S||-|
|dc.contributor.author||Keech, Anthony C||-|
|dc.identifier.citation||Ong KL, Januszewski AS, O'Connell R, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Hung WT, Scott RS, Taskinen MR, Keech AC, Rye KA. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia 2015; 58(3): 464-473.||en_AU|
|dc.description.abstract||Aims/hypothesis Circulating fibroblast growth factor 21 (FGF21) levels are often elevated in obesity, dyslipidaemia, insulin resistance and type 2 diabetes. This study investigated the relationship of plasma FGF21 levels with cardiovascular events in patients with type 2 diabetes.
Methods Plasma FGF21 levels were measured at baseline in 9,697 study participants with type 2 diabetes from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study by enzyme-linked immunosorbent assay. We assessed the association of FGF21 levels with incidence of different cardiovascular outcomes over 5-years. The primary outcome was total cardiovascular disease (CVD) events, and the secondary outcomes were the four individual components: coronary heart disease (CHD) events, total stroke, CVD mortality, coronary and carotid revascularization. Tertiary outcome was hospitalisation for angina pectoris.
Results Higher baseline FGF21 levels were associated with higher risks of all cardiovascular outcome events after adjusting for the study treatment allocation (all p<0.01). The associations remained significant for total CVD events, and coronary and carotid revascularisation after further adjusting for confounding factors with HR (95% CI) being 1.28 (1.10, 1.50) and 1.26 (1.01, 1.56) respectively, for the highest tertile compared to the lowest tertile (overall effect p=0.002 and 0.007 respectively). The addition of FGF21 levels to a model including established CVD risk factors predicting total CVD led to a non-significant increase in the C-statistic, but resulted in significant integrated discrimination improvement and net reclassification improvement.
Conclusions/interpretation Higher baseline plasma FGF21 levels were associated with higher risk of cardiovascular events in patients with type 2 diabetes.||en_AU|
|dc.relation||National Heart Foundation of Australia Grant-in-Aid G 12S 6681, NHMRC Program grants 482800, 103790, 10377863, Fellowship grant 1024105, University of New South Wales Vice-Chancellor’s Postdoctoral Fellowship.||en_AU|
|dc.subject||fibroblast growth factor 21||en_AU|
|dc.subject||type 2 diabetes||en_AU|
|dc.title||The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study||en_AU|
|dc.description.addcoll||Research papers and publications, NHMRC CTC||en_AU|
|Appears in Collections:||Research Papers and Publications. NHMRC CTC|